Table 1.
Clinical, demographical, and laboratory data of the groups
| Survived patients (n=221) (88.8%) | Dead patients (n=28) (11.2%) | All patients (n=249) (100%) | p | |
|---|---|---|---|---|
| Age | 63.6±18.3 (18–94) | 71.9±15.1 (32–92) | 64.5±18.0 (18–94) | 0.007 |
| Male (%) | 156 (70.6) | 16 (57.1) | 172 (69.1) | 0.147 |
| Hemoglobin (gr/dl) | 8.8±2.3 | 8.2±1.6 | 8.7±2.3 | 0.176 |
| White blood cell (x103) | 12.5±7.6 | 12.4±5.8 | 12.5±7.3 | 0.929 |
| Creatinine (mg/dl) | 1.3±1.1 | 1.9±2.1 | 1.4±1.4 | 0.015 |
| Blood urea nitrogen | 88.2±49.0 | 110.1±52.8 | 90.7±49.9 | 0.028 |
| Tachycardia (%) | 112 (50.7) | 24 (85.7) | 136 (54.6) | <0,001 |
| Hypotension(%) | 42 (19) | 19 (67.9) | 61 (24.5) | <0.001 |
| Rockall Score | 5.8±1.9 (2–10) | 8.3±1.2 (6–10) | 5.8±2.0 (2–10) | <0.001 |
| Glasgow-Blatchford Score | 11.7±3.2 (4–19) | 15.8±2.5 (9–19) | 12.2±3.3 (4–19) | <0.001 |
| Mean number of erythrocyte suspension transfusions | 2.8±3.2 (0–21) | 6.1±5.9 (1–25) | 3.2±3.7 (1–25) | <0.001 |
| Hospitalization (days) | 6.6±6.9 (1–55) | 8.3±5.3 (2–25) | 6.8± 6.6 (1–55) | 0.207 |
| Length of stay in intensive care unit (days) | 2.3±4.1 (0–28) | 6.3±4.8 (1–11) | 2.8±4.3 (0–28) | <0.001 |
| Drug use | 0.045 | |||
| Antitrombotic use (%) | 53 (24.0) | 14 (50) | 67 (26.9) | |
| Antitrombotic + anticoagulant use (%) | 16 (7.2) | 2 (7.1) | 18 (7.2) | |
| Non steroidal anti-inflammatory drug use (%) | 51 (23.1) | 3 (5.6) | 54 (21.7) | |
| Anticoagulant use (%) | 26 (11.3) | 1 (3.6) | 27 (10.8) | |
| Does not use (%) | 75 (33.9) | 8 (28.6) | 83 (33.3) | |
| Neutrophil lymphocyte ratio | 4.81±2.45 | 8.97±4.86 | 5.28±3.10 | <0.001 |
| Platelet lymphocyte ratio | 165.2±93.8 | 232.7±102.7 | 172.8±97.0 | <0.001 |
| Presence of chronic renal disease (%) | 26 (11.8) | 6 (21.4) | 32 (12.9) | 0.150 |
| Presence of diabetes mellitus (%) | 39 (17.6) | 5 (17.9) | 44 (17.7) | 0.978 |
| Presence of coronary artery disease (%) | 71 (32.1) | 13 (46.4) | 84 (33.7) | 0.132 |